CDKN2A and meningioma: Its loss has been implicated in dysregulated cell cycle progression in multiple cancers.96,97 In meningioma, homozygous deletion of CDKN2A/B is associated with significantly shorter PFS, and even heterozygous deletions have been found to be associated with similarly poor outcomes in some studies.98–101 In meningiomas with an intact CDKN2A/B locus, higher mRNA expression of CDKN2A was also associated with significantly shorter PFS and increased rates of resistance to CDK inhibitors.98